Daejeon Korean Medicine Hospital of Daejeon University, Daejeon, Republic of Korea.
Kyung Hee University Hospital at Gangdong, Gangdonggu, Seoul, Republic of Korea.
Integr Cancer Ther. 2021 Jan-Dec;20:15347354211019107. doi: 10.1177/15347354211019107.
The purpose of this study is both to estimate the efficacy and the safety of Yukgunja-tang (YGJT) and to establish evidence for the use of herbal medicines in the management of patients with cancer-related anorexia.
We enrolled 40 patients with cancer-related anorexia. The enrolled participants were randomly allocated to 2 groups: the control group (n = 20), which received nutrition counseling, and the treatment group (n = 20), which received nutrition counseling and was administered YGJT at twice a day for 4 weeks (a total of 56 times @ 3.0 g each time). The primary outcome of this study was the score on the anorexia/cachexia subscale (ACS) of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT). The secondary outcomes were the FAACT score with the ACS score excluded, the score on the Visual Analog Scale (VAS) for appetite, and the results on laboratory tests regarding appetite, such as leptin, tumor necrosis factors (TNF-α), interleukin-6 (IL-6), and ghrelin. All variables related to the safety assessment, such as vital signs, electrocardiography results, laboratory test results (complete blood cell count, chemistry, urine test), and adverse events, were documented on the case report form (CRF) at every visit.
The difference in the primary outcome, that is, the score on the anorexia/cachexia subscale (ACS) of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT), between the control and the treatment groups was statistically significant ( = .023) as was the difference in the FAACT scores with the ACS score excluded, a secondary outcome, between the 2 groups; however, no statistically significant differences were noted in the scores on the VAS or the levels of leptin, TNF-α, IL-6, and ghrelin. In addition, no significant differences in the numbers and the types of adverse events or in the results on the laboratory tests between the control and the treatment groups were recorded.
These results obtained in this research confirmed the efficacy and the safety of using YGJT as a herb-medicine treatment option for patients with cancer-related anorexia.
本研究旨在评估玉井散(YGJT)的疗效和安全性,并为癌症相关性厌食患者的草药治疗提供证据。
我们纳入了 40 例癌症相关性厌食患者。将入组患者随机分为 2 组:对照组(n=20)接受营养咨询,治疗组(n=20)在接受营养咨询的基础上,每日口服 YGJT 2 次,共 4 周(共 56 次,每次 3.0g)。本研究的主要结局是厌食/恶病质量表(ACS)的评分。次要结局是排除 ACS 评分后的 FAACT 评分、食欲视觉模拟量表(VAS)评分以及与食欲相关的实验室检查结果,如瘦素、肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)和 ghrelin。每次就诊时,均将与安全性评估相关的所有变量(生命体征、心电图结果、实验室检查结果[全血细胞计数、化学检查、尿液检查]和不良事件)记录在病例报告表(CRF)上。
治疗组和对照组在主要结局(即厌食/恶病质量表(ACS)的功能评估厌食/恶病质疗法(FAACT)评分)方面的差异具有统计学意义(P=0.023),在排除 ACS 评分后的 FAACT 评分(次要结局)方面的差异也具有统计学意义;然而,两组患者 VAS 评分或瘦素、TNF-α、IL-6 和 ghrelin 水平的差异无统计学意义。此外,对照组和治疗组之间的不良事件数量和类型以及实验室检查结果均无显著差异。
本研究结果证实了 YGJT 作为癌症相关性厌食患者草药治疗选择的疗效和安全性。